Logistic regression with depression (CES-D ≥16) as the outcome, inclusive of unadjusted models and models adjusted for confounding factors in the total population.

<p>Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes (WHO 2006 criteria).</p><p>*Denotes reference category.</p

Prevalence and mean scores of depressive symptoms and anxiety by glucose metabolism status for the total study population and stratified according to sex.

<p>Data are %, means ± SD. P  =  p-values based on one-way ANOVA for continuous variables and χ²-tests for categorical variables. ^a significantly different comparing IGM vs. DM2. Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes; SD, standard deviation; HADS-A. Hospital Anxiety and Depression Scale – Anxiety Subscale; CES-D, Center for Epidemiologic Studies Depression Scale.</p

Odds ratios for depression (CES-D score ≥16) and anxiety (HADS-A ≥16) by sex with impaired glucose metabolism or type 2 diabetes subjects compared with normal glucose metabolism subjects.

<p>Abbreviations: NGM, normal glucose metabolism; IGM, impaired glucose metabolism; DM2, type 2 diabetes (WHO 2006 criteria).</p>*<p>The unadjusted odds ratios.</p>§<p>Model 1: Adjusted for age, education and family history of diabetes.</p>¶<p>Model 2: Adjusted for Model 1 and triglycerides, HDL cholesterol, and total cholesterol.</p>†<p>Model 3. Adjusted for Model 2 and, hypertension, smoking and waist circumference.</p

Explained variance after internal validation.

<p>Explained variance after internal validation.</p

Calibration graphs (in deciles) of the prediction model after internal validation.

<p>(A) For men, in the development dataset (The Hoorn Study, The KORA S4/F4 Study and the Inter99 Study combined). (B) For men, in the development dataset, stratified per cohort: Hoorn Study (dots), KORA F4/S4 Study (squares), Inter99 Study (triangles). (C) For women, in the development dataset (The Hoorn Study, The KORA S4/F4 Study and the Inter99 Study combined). (D) For women, in the development dataset, stratified per cohort: Hoorn Study (dots), KORA F4/S4 Study (squares), Inter99 Study (triangles). (E) For men, in the external validation dataset (The METSIM Study). The diagonal line indicates perfect calibration.</p

Linear regression model predicting HbA1c levels after 6 years.

<p>Linear regression model predicting HbA1c levels after 6 years.</p

Baseline characteristics of the 4 datasets.

<p>Baseline characteristics of the 4 datasets.</p

Effects of the Framingham risk factors in race/ethnic groups for the outcomes log CIMT (betas) and CV events (hazard ratios).

<p>The top half of the table displays betas and 95% confidence intervals of the Framingham risk factors for log CIMT for each race/ethnic group. The bottom half of the table displays hazard ratios and 95% confidence intervals of the Framingham risk factors for CV events for each race/ethnic group. The % difference columns express the percentage difference in effect size (beta or hazard ratio) as compared to the White race/ethnic group. Risk factors printed in bold have significantly different effect sizes among race/ethnic groups (significant interaction).</p><p>^a Indicates significant difference as compared to Whites (p<0.05)</p><p>^b Cardiovascular events (first-time stroke or MI).</p><p>Effects of the Framingham risk factors in race/ethnic groups for the outcomes log CIMT (betas) and CV events (hazard ratios).</p

Association between risk factors and mean common CIMT, by ethnicity.

<p>Point estimates for betas, lines represent 95% confidence intervals.</p

Details of participating USE-IMT cohorts.

<p>Abbreviations. ARIC: Atherosclerosis Risk in Communities Study; CAPS: Carotid Atherosclerosis Progression Study; CHS: Cardiovascular Health Study; CIRCS: Circulatory Risk in Communities Study; EAS: Edinburgh Artery Study; FATE: The Firefighters and Their Endothelium Study; Hoorn: The Hoorn Study; KIHD: Kuopio Ischaemic Heart Disease Risk Factor Study; Malmö: Malmö Diet and Cancer Study, MESA; Multi-race/ethnic Study of Atherosclerosis; NBS: Nijmegen Biomedical Study 2; NOMAS: Northern Manhattan Study; OSACA2: Osaka Follow-Up Study for Carotid Atherosclerosis 2; Tromsø: Tromsø Study; Whitehall: Whitehall II Study; CIMT: mean common carotid intima media thickness; FU: follow-up duration; MI: myocardial infarction; USA: United States of America; UK: United Kingdom; NLD: The Netherlands.</p><p>Details of participating USE-IMT cohorts.</p